A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I/III Limited Disease Small-Cell Lung

Grants and Contracts Details

StatusActive
Effective start/end date7/26/196/14/23

Funding

  • AstraZeneca Pharmaceuticals AB: $74,327.00